◆ TICKERBASE交互式视图 →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

首页全部股票 › INCY · English version

Incyte Corporation (INCY)

来自官方财务报表的收入、利润与现金流历史。

Health Care · 华尔街(美国) · 最近更新: 2026-09-19

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

关键数据

查看交互式图表与完整报表 → 估值模型 (DCF) →

年度利润表

利润表TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
总收入$5.8B$5.1B$4.2B$3.7B$3.4B$3.0B$2.7B$2.2B$1.9B$1.5B$1.1B$754M$511M$355M$297M$94M$170M$9M$4M$34M$28M
毛利$5.4B$4.8B$3.9B$3.4B$3.2B$2.8B$2.5B$2.0B$1.8B$1.5B$1.0B$727M$508M$354M$297M$94M$170M$9M$4M$34M$28M
毛利率%92.6%92.8%92.6%93.1%93.9%94.9%95.1%94.7%95.0%94.8%94.7%96.4%99.4%99.8%100.0%100.0%100.0%100.0%100.0%100.0%100.0%
营业利润(EBIT)$1.8B$1.3B$101M$655M$592M$586M($264M)$402M$129M($243M)$145M$51M($5M)($16M)$1M($143M)$14M($140M)($159M)($85M)($77M)
营业利润率%31.6%26.1%2.4%17.7%17.4%19.6%-9.9%18.6%6.9%-15.8%13.1%6.7%-0.9%-4.5%0.4%-151.6%8.3%-1508.6%-4064.5%-247.6%-278.1%
净利$1.6B$1.3B$33M$598M$341M$949M($296M)$447M$109M($313M)$104M$7M($48M)($83M)($44M)($187M)($32M)($212M)($179M)($87M)($74M)
净利润率 %27.7%25.0%0.8%16.2%10.0%31.8%-11.1%20.7%5.8%-20.4%9.4%0.9%-9.5%-23.4%-14.9%-197.5%-18.8%-2286.8%-4565.4%-252.3%-268.3%
EBITDA$1.8B$408M$919M$600M$630M($178M)$543M$172M($253M)$205M$98M$40M($15M)$32M($116M)$36M($123M)($146M)($72M)($69M)
每股收益(EPS)$7.85$6.41$0.15$2.65$1.52$4.27$-1.36$2.05$0.51$-1.53$0.54$0.03$-0.29$-0.56$-0.34$-1.49$-0.26$-2.06$-1.99$-1.03$-0.89
已发行股数 (M)201M211M226M224M222M218M218M216M205M194M187M168M148M130M125M122M103M90M84M84M

来源:公司公开报告(SEC)。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 INCY 交互式查看器。 /companies/us/INCY

类似公司

本网站信息仅用于教育与参考,不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.